by Garth Sundem | Sep 16, 2019 | Featured, Research
Since the 1940’s, blocking the body’s production of androgen has been the only systemic therapy against prostate cancer. Today, while we’ve gotten better at targeting androgen signaling, treatments targeting the genetic causes of prostate cancer have lagged behind...
by Garth Sundem | Sep 12, 2019 | Featured, Honors
The Costello lab, James Costello, PhD, at left The National Cancer Institute (NCI) is set up to fund individual projects in fields like genomics, computational biology, and pathology. Now researchers at University of Colorado Cancer Center are taking advantage of an...
by Taylor Abarca | Jun 4, 2019 | Featured, Patient Care
For most people finding out that they have prostate cancer multiple times in the span of just a few years seem like a cruel joke. But Jonathan Ormes is not most people. After being told for the third time that he had the disease he decided to take a chance on a...
by Garth Sundem | Apr 16, 2018 | Latest News, Research
When prostate cancer metastasizes to bone, it can become especially dangerous – not only with its action in the bone but, interestingly, with increased aggressiveness of the overall cancer itself. Now, research presented at the American Association for Cancer Research...
by Garth Sundem | Aug 4, 2017 | Latest News, Research
The chemotherapy docetaxel is widely accepted as a standard therapy for metastatic castration-resistant prostate cancer. But 10-20 percent of patients will have adverse side effects that force discontinuation of treatment. These patients may have been better off with...
